ACADIA Pharmaceuticals, a biopharmaceutical company developing innovative medicines to address unmet medical needs in central nervous system disorders, announced the acquisition of CerSci Therapeutics, a company focused on the development of non-opioid medicines to treat acute post-operative and chronic neuropathic pain. Through this deal, ACADIA acquired non-opioid pain medicine at Phase 1, as well as several preclinical programs in painful diabetic neuropathy, migraine, neurodegenerative diseases and opioid use disorders.
The lead development program of CerSci was CT-044 (now ACP-044), a powerful reactive species decomposition accelerant preventing hyper-activation of TRPA1, to treat acute post-operative and chronic neuropathic pain. This molecule has shown promising efficacy and safety results in animal models as well as favorable tolerability and pharmacokinetic properties in Phase 1 trials.
ACADIA plans to initiate a Phase 2 clinical study in the first half of 2021.
Read more about ACADIA Pharmaceuticals here.
Read more about CerSci Therapeutics here.
Image by Narcis Ciocan from Pixabay
